Navelbine (Vinorelbine Tartrate)

Vinorelbine is a Vinca alkaloid used in the management of solid tumours that rely on rapid cell division.

• Non‑small cell lung cancer: improves disease control when used in combination chemotherapy regimens.
• Metastatic breast cancer: provides benefit after prior anthracycline or taxane therapy.
• Advanced solid tumours: may be considered in selected cases where other options are limited.

• Vinorelbine binds to tubulin, inhibiting microtubule polymerisation and thereby preventing the formation of the mitotic spindle. This blockade arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells.

Vinorelbine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional episodes, often controllable with anti‑emetics.
• Neutropenia: reduced white blood cell count, increasing infection risk.
• Anemia: lowered red blood cell levels causing fatigue.
• Fatigue: general tiredness during treatment.
• Alopecia: hair thinning or loss.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection: requires immediate medical attention.
• Pulmonary toxicity: breathlessness or cough indicating lung injury.
• Hypersensitivity reactions: rash, itching, or anaphylaxis.
• Cardiac arrhythmia: irregular heartbeats observed in some patients.
• Severe hypotension: sudden drop in blood pressure during infusion.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

• Blood count monitoring: perform regular CBC to detect neutropenia or anemia.
• Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically.
• Cardiac evaluation: baseline ECG recommended for patients with cardiac history.
• Infection risk: avoid use in patients with active severe infections.
• Renal impairment caution: adjust monitoring in patients with reduced kidney function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine plasma levels.
• High‑dose corticosteroids: may potentiate neutropenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters.
• Antiemetic agents (e.g., ondansetron): assess for additive QT prolongation risk.